Nebula Research & Development’s Nurix Therapeutics NRIX Stock Holding History

Nebula Research & Development’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,894	Closed	-$133K	–	914
2023 Q4	$133K	Buy	+12,894	New	+$88.4K	0.04%	586
2023 Q3	–	Sell	-16,025	Closed	-$160K	–	609
2023 Q2	$160K	Buy	+16,025	New	+$163K	0.12%	283

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Nebula Research & Development's NRIX Position: Q1 2024 in Review

Nebula Research & Development sold out of Nurix Therapeutics (NRIX) in Q1 2024, closing a stake of 12,894 shares — an estimated $133K sold.

Nebula Research & Development first reported a position in NRIX in Q2 2023 and held it in 2 quarters. The position peaked at $160K in Q2 2023. 139 funds tracked by Wall St. Rank hold NRIX as of Q1 2024.

Nebula Research & Development reported no remaining Nurix Therapeutics position as of Q1 2024 after selling out during the quarter.
Nebula Research & Development sold 12,894 Nurix Therapeutics shares in Q1 2024, an estimated $133K.
Nebula Research & Development first reported a position in Nurix Therapeutics in Q2 2023 and held it in 2 quarters.
Nebula Research & Development's Nurix Therapeutics position peaked at $160K in Q2 2023.
139 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2024.

Based on Nebula Research & Development's 13F filing for Q1 2024, filed 15 May 2024.